JP2019503387A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019503387A5 JP2019503387A5 JP2018539118A JP2018539118A JP2019503387A5 JP 2019503387 A5 JP2019503387 A5 JP 2019503387A5 JP 2018539118 A JP2018539118 A JP 2018539118A JP 2018539118 A JP2018539118 A JP 2018539118A JP 2019503387 A5 JP2019503387 A5 JP 2019503387A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding portion
- ctla
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims 22
- 102000036639 antigens Human genes 0.000 claims 22
- 108091007433 antigens Proteins 0.000 claims 22
- 239000002246 antineoplastic agent Substances 0.000 claims 17
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 10
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 10
- 230000000694 effects Effects 0.000 claims 7
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 6
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 5
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 4
- 201000005202 lung cancer Diseases 0.000 claims 4
- 208000020816 lung neoplasm Diseases 0.000 claims 4
- 238000001802 infusion Methods 0.000 claims 3
- 229960005386 ipilimumab Drugs 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229960003301 nivolumab Drugs 0.000 claims 2
- 229960002621 pembrolizumab Drugs 0.000 claims 2
- 229950007217 tremelimumab Drugs 0.000 claims 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 1
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 102000043321 human CTLA4 Human genes 0.000 claims 1
- 102000048362 human PDCD1 Human genes 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021210901A JP2022046649A (ja) | 2016-01-27 | 2021-12-24 | 抗ｐｄ－１抗体および別の抗癌剤の組合せを用いる肺癌の処置法 |
| JP2024108149A JP2024133611A (ja) | 2016-01-27 | 2024-07-04 | 抗ｐｄ－１抗体および別の抗癌剤の組合せを用いる肺癌の処置法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662287717P | 2016-01-27 | 2016-01-27 | |
| US62/287,717 | 2016-01-27 | ||
| PCT/US2017/015333 WO2017132508A1 (en) | 2016-01-27 | 2017-01-27 | Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021210901A Division JP2022046649A (ja) | 2016-01-27 | 2021-12-24 | 抗ｐｄ－１抗体および別の抗癌剤の組合せを用いる肺癌の処置法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019503387A JP2019503387A (ja) | 2019-02-07 |
| JP2019503387A5 true JP2019503387A5 (enExample) | 2020-03-05 |
Family
ID=58163189
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018539118A Pending JP2019503387A (ja) | 2016-01-27 | 2017-01-27 | 抗ｐｄ−１抗体および別の抗癌剤の組合せを用いる肺癌の処置法 |
| JP2021210901A Pending JP2022046649A (ja) | 2016-01-27 | 2021-12-24 | 抗ｐｄ－１抗体および別の抗癌剤の組合せを用いる肺癌の処置法 |
| JP2024108149A Pending JP2024133611A (ja) | 2016-01-27 | 2024-07-04 | 抗ｐｄ－１抗体および別の抗癌剤の組合せを用いる肺癌の処置法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021210901A Pending JP2022046649A (ja) | 2016-01-27 | 2021-12-24 | 抗ｐｄ－１抗体および別の抗癌剤の組合せを用いる肺癌の処置法 |
| JP2024108149A Pending JP2024133611A (ja) | 2016-01-27 | 2024-07-04 | 抗ｐｄ－１抗体および別の抗癌剤の組合せを用いる肺癌の処置法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20210206854A1 (enExample) |
| EP (1) | EP3408296A1 (enExample) |
| JP (3) | JP2019503387A (enExample) |
| KR (1) | KR20180101584A (enExample) |
| CN (1) | CN108602892A (enExample) |
| WO (1) | WO2017132508A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| CN105296433B (zh) | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | 一种ctla4抗体、其药物组合物及其用途 |
| WO2016176503A1 (en) | 2015-04-28 | 2016-11-03 | Bristol-Myers Squibb Company | Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody |
| EP3288980B1 (en) * | 2015-04-28 | 2021-03-10 | Bristol-Myers Squibb Company | Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody |
| MX383464B (es) | 2015-07-13 | 2025-03-14 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos. |
| MX392711B (es) | 2015-08-11 | 2025-03-24 | Wuxi Biologics Ireland Ltd | Anticuerpos anti-pd-1 novedosos. |
| JP6869987B2 (ja) | 2015-09-01 | 2021-05-12 | アジェナス インコーポレイテッド | 抗ｐｄ−１抗体及びその使用方法 |
| US11072657B2 (en) | 2015-11-18 | 2021-07-27 | Bristol-Myers Squibb Company | Treatment of lung cancer using a combination of an anti-PD-1 antibody and an anti-CTLA-4 antibody |
| WO2018035710A1 (en) | 2016-08-23 | 2018-03-01 | Akeso Biopharma, Inc. | Anti-ctla4 antibodies |
| CN110300599B (zh) | 2016-12-07 | 2024-07-02 | 艾吉纳斯公司 | 抗体和其使用方法 |
| US12668635B1 (en) | 2017-11-21 | 2026-06-30 | Arcus Biosciences, Inc. | Methods of treating solid tumors using an anti-PD-1 antibody or a fragment thereof |
| WO2019157124A1 (en) * | 2018-02-08 | 2019-08-15 | Bristol-Myers Squibb Company | Combination of a tetanus toxoid, anti-ox40 antibody and/or anti-pd-1 antibody to treat tumors |
| SG11202007590TA (en) | 2018-02-13 | 2020-09-29 | Merck Sharp & Dohme | Methods for treating cancer with anti-pd-1 antibodies |
| EP3774911A1 (en) * | 2018-03-30 | 2021-02-17 | Bristol-Myers Squibb Company | Methods of treating tumor |
| KR102673786B1 (ko) | 2018-08-28 | 2024-06-07 | 주식회사 엘지에너지솔루션 | 원통형 전지 및 이의 제조 방법 |
| BR112021008549A2 (pt) * | 2018-11-05 | 2022-01-04 | Iovance Biotherapeutics Inc | Método de tratamento de carcinoma pulmonar de células não pequenas com uma população de linfócitos infiltrantes de tumor |
| AR122043A1 (es) * | 2020-05-12 | 2022-08-03 | Bristol Myers Squibb Co | Dosificación y administración del anticuerpo anti-ctla-4 activable |
| CA3196496A1 (en) | 2020-10-23 | 2022-04-28 | Laurence David TOMS | Lag-3 antagonist therapy for lung cancer |
| CN113945723B (zh) * | 2021-10-28 | 2024-03-12 | 复旦大学附属中山医院 | 预测免疫检查点抑制剂治疗相关肺炎发生风险的系统、储存介质及其应用 |
| CN117899200B (zh) * | 2022-10-18 | 2025-11-07 | 华中科技大学 | 用于增强免疫治疗疗效的药物及其治疗肿瘤之应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3530736A3 (en) * | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| BR112015007184A2 (pt) * | 2012-10-02 | 2017-08-08 | Bristol Myers Squibb Co | combinação de anticorpos anti-kir e anticorpos anti-pd-1 para tratar câncer |
| UA122479C2 (uk) * | 2014-01-24 | 2020-11-25 | Дана-Фарбер Кенсер Інстітьют, Інк. | Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1) |
| CN107073090A (zh) * | 2014-04-30 | 2017-08-18 | 哈佛学院董事会 | 结合的疫苗装置和杀死癌细胞的方法 |
| JP2017515859A (ja) * | 2014-05-15 | 2017-06-15 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｐｄ−１抗体と他の抗癌剤の組み合わせを使用する肺癌の処置 |
| WO2016011357A1 (en) * | 2014-07-18 | 2016-01-21 | Advaxis, Inc. | Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer |
| AU2016271111B2 (en) * | 2015-05-29 | 2022-04-28 | Bristol-Myers Squibb Company | Antibodies against OX40 and uses thereof |
| WO2019140150A1 (en) * | 2018-01-12 | 2019-07-18 | Bristol-Myers Squibb Company | Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer |
-
2017
- 2017-01-27 EP EP17707430.9A patent/EP3408296A1/en active Pending
- 2017-01-27 WO PCT/US2017/015333 patent/WO2017132508A1/en not_active Ceased
- 2017-01-27 KR KR1020187024200A patent/KR20180101584A/ko not_active Ceased
- 2017-01-27 CN CN201780008860.1A patent/CN108602892A/zh active Pending
- 2017-01-27 US US16/073,676 patent/US20210206854A1/en not_active Abandoned
- 2017-01-27 JP JP2018539118A patent/JP2019503387A/ja active Pending
-
2021
- 2021-12-24 JP JP2021210901A patent/JP2022046649A/ja active Pending
-
2022
- 2022-08-08 US US17/818,298 patent/US20230083487A1/en not_active Abandoned
-
2024
- 2024-07-04 JP JP2024108149A patent/JP2024133611A/ja active Pending
-
2025
- 2025-09-29 US US19/343,049 patent/US20260092114A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017507155A5 (enExample) | ||
| JP2018500332A5 (enExample) | ||
| ES2912131T3 (es) | Uso de agentes moduladores del glutamato con inmunoterapias para tratar el cáncer | |
| JP2014533279A5 (enExample) | ||
| RU2016148927A (ru) | Лечение рака легкого с помощью комбинации антитела против pd-1 и другого противоракового средства | |
| JP2019517498A5 (enExample) | ||
| JP2025185043A (ja) | 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与 | |
| JP2012102122A5 (enExample) | ||
| JP2019517512A5 (enExample) | ||
| JP2018516969A5 (enExample) | ||
| JP2016520082A5 (enExample) | ||
| JP2009518441A5 (enExample) | ||
| JP2019517505A5 (enExample) | ||
| RS59134B1 (sr) | Anti-b7-h1 i anti-ctla-4 antitela za tretman nesitnoćelijskog kancera pluća | |
| WO2018223923A1 (zh) | Pd-1抗体与vegf配体或vegf受体抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2013520442A5 (enExample) | ||
| CA2939464A1 (en) | Use of anti-ccr5 antibodies in graft versus host disease | |
| JP2015500822A5 (enExample) | ||
| JP2020023499A (ja) | 抗ｃｘｃｒ４抗体によるｃ１０１３ｇ／ｃｘｃｒ４関連ワルデンシュトレームマクログロブリン血症の治療 | |
| WO2018112407A1 (en) | Antibodies and methods for depleting regulatory b10 cells and use in combination with immune checkpoint inhibitors | |
| JP2019508433A5 (enExample) | ||
| JP2022512851A5 (enExample) | ||
| JP2020059703A (ja) | 免疫除去療法 | |
| JP2019517504A5 (enExample) | ||
| CN112351795A (zh) | 采用抗癌药剂和以包含非典型hla-i及新抗原复合物为靶点的抗体的联合抗癌疗法 |